scholarly journals Positive nodal status is still a risk factor for long-term survivors of non-small cell lung cancer 5 years after complete resection

2021 ◽  
Vol 0 (0) ◽  
pp. 0-0
Author(s):  
Young Ho Yang ◽  
Ha Eun Kim ◽  
Byung Jo Park ◽  
Seokkee Lee ◽  
Seong Yong Park ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Risk Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Complete Resection ◽  
Small Cell ◽  
Small Cell Lung ◽  
Positive Nodal Status ◽  
Long Term Survivors

scholarly journals Long-term survivors with pN2 non-small cell lung cancer after a complete resection with a systematic mediastinal node dissection

1998 ◽  
Vol 14 (2) ◽  
pp. 152-155 ◽  
Author(s):  
Tokujiro Yano ◽  
Yasuro Fukuyama ◽  
Hideki Yokoyama ◽  
Shinji Kuninaka ◽  
Yasuhiro Terazaki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Complete Resection ◽  
Small Cell ◽  
Node Dissection ◽  
Small Cell Lung ◽  
Mediastinal Node ◽  
Long Term Survivors

Erythroleukemia and other hematologic complications of intensive therapy in long-term survivors of small cell lung cancer

Cancer ◽  
1982 ◽  
Vol 49 (2) ◽  
pp. 221-223 ◽  
Author(s):  
Edward C. Bradley ◽  
Geraldine P. Schechter ◽  
Mary J. Matthews ◽  
Jacqueline Whang-Peng ◽  
Martin H. Cohen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Intensive Therapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Long Term Survivors

Adjuvant vinorelbine and cisplatin after complete resection of stage II and III non-small cell lung cancer: long-term follow-up of our study of Japanese patients

Surgery Today ◽  
2018 ◽  
Vol 48 (7) ◽  
pp. 687-694 ◽  
Author(s):  
Makoto Sonobe ◽  
Masatsugu Hamaji ◽  
Hideki Motoyama ◽  
Toshi Menju ◽  
Akihiro Aoyama ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Japanese Patients ◽  
Complete Resection ◽  
Small Cell ◽  
Small Cell Lung ◽  
Long Term Follow Up

scholarly journals EP1.01-07 Definitive Results of a Clinical and Molecular Multicentric Characterization of Long-Term Survivors with Advanced Non-Small Cell Lung Cancer

2019 ◽  
Vol 14 (10) ◽  
pp. S917
Author(s):  
J. Moreno-Rubio ◽  
S. Ponce ◽  
R. Alvarez ◽  
M.E. Olmedo ◽  
S. Falagan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Long Term Survivors

Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors

2019 ◽  
Vol 68 (3) ◽  
pp. 341-352 ◽  
Author(s):  
Ernest Nadal ◽  
Bartomeu Massuti ◽  
Manuel Dómine ◽  
Rosario García-Campelo ◽  
Manuel Cobo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Checkpoint Inhibitors ◽  
Small Cell ◽  
Small Cell Lung ◽  
Long Term Survivors

Prognostic factors identified in the long term survivors with limited small cell lung cancer

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 7552-7552
Author(s):  
R. Komaki ◽  
P. K. Allen ◽  
X. Wei ◽  
Z. Liao ◽  
J. Y. Chang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factors ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Long Term Survivors

Neurological and cognitive impairment in long term survivors of small cell lung cancer (SCLC)

1993 ◽  
Vol 29 ◽  
pp. S154
Author(s):  
A Cull ◽  
A Gregor ◽  
P Hopwood ◽  
N Thatcher ◽  
F McBeth ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cognitive Impairment ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Long Term Survivors

scholarly journals P3.01-88 Clinical and Molecular Analysis of Long-Term Survivors with Advanced Non-Small Cell Lung Cancer: A Multicenter Experience in Madrid

2018 ◽  
Vol 13 (10) ◽  
pp. S900
Author(s):  
M. Sereno Moyano ◽  
S. Falagan ◽  
J. Moreno Rubio ◽  
R. Álvarez Álvarez ◽  
M.E. Olmedo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Molecular Analysis ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Long Term Survivors

Secondary primary cancer in the long-term survivors with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 7147-7147
Author(s):  
N. Takigawa ◽  
Y. Segawa ◽  
K. Kiura ◽  
M. Tabata ◽  
H. Ueoka ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
Small Cell ◽  
Small Cell Lung ◽  
Primary Nsclc ◽  
Long Term Survivors

7147 Background: Although concurrent chemoradiotherapy (CT/RT) is associated with increased survival for patients (pts) with locally advanced non-small cell lung cancer (NSCLC), long-outcomes beyond 5 years have not been fully analyzed. Methods: Between 1994 and 1999, we conducted two phase II studies examining concurrent CT/RT for treatment of surgically unresectable stage IIIA or IIIB NSCLC. One regimen consisted of three cycles of 5-fluorouracil 500mg/m2 and cisplatin 20mg/m2, days 1–5, every 4 weeks and concurrent hyperfractionated thoracic RT (1.25Gy twice daily, total 62.5–70Gy) [FP-TRT] (Segawa et al. BJC 82, 2000). The other consisted of docetaxel 40mg/m2 and cisplatin 40mg/m2, days 1, 8, 29 and 36 and concurrent thoracic RT (2Gy daily, total 60Gy) [DP-TRT] (Kiura et al. BJC 89, 2003). Long-term data is presented. Results: In 50 pts treated with FP-TRT, the median survival time (MST) was 1.6 years (yr; 95% confidential interval [CI]: 0.91 - 2.25 yr) by a median follow-up time of 10.4 yr and the actual 5 yr-survival rate was 30%. In 15 long-term survivors, 3 and 2 pts died due to primary NSCLC and secondary primary cancer (SPC), respectively, 1 was lost to follow-up, and 9 are still alive. In 42 pts treated with DP-TRT, the MST was 2.1 yr (95% CI: 0.82 - 2.48 yr) by a median follow-up time of 6.3 yr and the actual 5 yr-survival rate was 31%. In 13 long-term survivors, 1 pt died due to primary NSCLC, 1 died due to SPC, 1 was lost to follow-up, and 10 are still alive. Overall, 7 of 92 pts enrolled in these studies developed SPCs (2 NSCLC, 1 small cell lung cancer, 2 esophageal cancers, 2 gall bladder cancers) although no pts developed leukemia or myelodysplastic syndrome. An observed incidence rate of SPCs was 2356.1/100,000 (95% CI: 947.6 - 4856.0). Cumulative incidence was 5.8% (standard error [SE] 4.0%) at 5 yr, 10.0% (SE 5.6%) at 8 yr and 60.8% (SE 18.9%) at 10 yr. The median time from the beginning of CT/RT to the diagnosis of SPC was 9.6 yr (95% CI: 8.1 - 11.1 yr). Conclusions: Approximately 30% of pts survived more than 5 years after concurrent CT/RT, however, they were still at risk of dying from primary NSCLC. Occurrence of SPC in long-term survivors should be concerned in follow-up. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document